Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunothe... (so developing a new class of drugs for t...)

Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel

Date:2/5/2008

so developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead candidate from this new class of drugs.

Certain statements contained in this press release, the upcoming webcast, or elsewhere in our public documents constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and/or "forward-looking information" under the Securities Act (Ontario). These statements may include, without limitation, plans to advance the development of Celacade(TM) or VP025, plans to fund our current activities, statements concerning our partnering activities, health regulatory submissions, strategy, future operations, future financial position, future revenues and projected costs. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expects", "plans", "anticipates", "believes", "estimated", "predicts", "potential", "continue", "intends", "could", or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of these forward-looking statements, including assumptions about the nature, size, and accessibility of the market for Celacade in the treatment of chronic heart failure, particularly in Europe, the regulatory approval process leading to commercialization and the availability of capital on acceptable terms to pursue the development of Celacade, and the feasibility of additional trials. You should not place undue reliance on our forward-looking statements which are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those projected. These risks include, but are not limited to, the outcome of further ongoing analysis of the ACCLAIM trial results, the requirement or election to conduct additional clinical trials and the size and design of any such trials, delays or setbacks
'/>"/>

SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3
Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Vasogen Announces 2007 Year-End Results
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogens Research Published in European Journal of Neuroscience
10. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
11. Avicena Group to Present at Noble Financial Conference

Post Your Comments:

(Date:12/16/2009)... has been found to be effectinve in improving yelds of probiotic ... ... BioSciences, LLC. ( www.nu-tekproducts.com ) is meeting the demand for Non-Animal ... Nutricepts, Inc. (Burnsville, Mn), is a high quality Soy Peptone. ... has been found to be especially effective in improving yields of ...

(Date:12/15/2009)... one of three Department of Energy (DOE) bio-energy research ... protect its valuable intellectual property. , ... ... 2009 -- Surety, LLC , the leading provider ... that the Joint BioEnergy Institute (JBEI), one of three ...

(Date:12/15/2009)... YORK, Dec. 15 Reportlinker.com announces ... available in its catalogue: ,, ... Market Forecasts to 2015, Pipeline Analysis and ... ,, Summary ... research "The Future of Orphan Diseases Therapeutics ...

(Date:12/15/2009)... (AFM) have been developed and are opening up a new ... The NeedleProbes’ cylindrical geometry enables researchers to measure surface tension, ... in a single force distance curve. , ... ... NeedleProbes are enabling unique measurements at the liquid/air ...

[0] Nu-Tek BioSciences, LLC. Launches Animal-Free, Non-GM Soy Peptone [0] Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property [0] Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement [0] New Constant Diameter NeedleProbes™ with Unique Ability to Measure Liquid Surface Properties by AFM

... MOUNTAIN VIEW, Calif., Oct. 14 Clontech Laboratories,Inc., ... the three,winners of the 2008 Nobel Prize in ... Tsien, for the discovery and development of the ... related fluorescent proteins.,The application of fluorescent proteins as ...

... divisions that include in vitro diagnostics, cancer therapeutics and ... ... Oct. 14 ( http://www.amdl.com ),AMDL, Inc. (Amex: ADL ), ... US, today announced it has restructured,its business into three distinct divisions ...

... Oct. 14 Nyer Medical Group,Inc. (Nasdaq: NYER ) ... for the fiscal year ended June 30, 2008 increased $6.6,million ... for the,previous fiscal year. Net loss for the fiscal year ... compared to a net income of $86,446 or $.02,per share ...

Other Biology Technology:Clontech Laboratories, Inc. Recognizes the 2008 Winners of the Nobel Prize in Chemistry 2 AMDL, Inc. Announces Strategic Realignment 2 AMDL, Inc. Announces Strategic Realignment 3 Nyer Medical Group, Inc. Reports Revenues of $71.2 Million With Net Loss of $.10 Per Share for Fiscal Year 2008 2 Nyer Medical Group, Inc. Reports Revenues of $71.2 Million With Net Loss of $.10 Per Share for Fiscal Year 2008 3

Clontech Laboratories, Inc. Recognizes the 2008 Winners of the Nobel Prize in Chemistry AMDL, Inc. Announces Strategic Realignment Nyer Medical Group, Inc. Reports Revenues of $71.2 Million With Net Loss of $.10 Per Share for Fiscal Year 2008

(Date:12/16/2009)... financial and technical assistance to developing countries around the ... be connected to space technology, but large development projects ... , Global climate change is also an increasingly important ... poorest countries and communities, which will suffer the earliest ... a growing demand for information about the state of ...

(Date:12/16/2009)... 15, 2009 Signal Hill, CA Tom Bowman, ... and president of Bowman Global Change, has developed a ... fourth Intergovernmental Panel on Climate Change (IPCC) report for ... the authentic scientific information they need to make informed ... created the new format as a means to clearly ...

(Date:12/16/2009)... Calif. and PALM HARBOR, Fla., Dec. 2 ... Bulletin Board: CICI), a leading supplier of ... in the financial industry* and the recognized ... Systems Inc. ("Docubase"), a leading International Electronic ... that they have entered an agreement to ...

Breaking Biology News(10 mins):ESA and World Bank move toward closer collaboration 2 ESA and World Bank move toward closer collaboration 3 ESA and World Bank move toward closer collaboration 4 Bowman creates graphic translation of climate change data 2 CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 2 CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 3 CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 4 Gentiva 28R 29 Health Services Schedules Second Quarter Earnings Call and Web Cast for Thursday July 30 2009 51438 1 Gentiva 28R 29 Health Services Schedules Second Quarter Earnings Call and Web Cast for Thursday July 30 2009 51438 2 Gentiva 28R 29 Health Services Schedules Second Quarter Earnings Call and Web Cast for Thursday July 30 2009 51438 3 Gentiva 28R 29 Health Services Schedules Second Quarter Earnings Call and Web Cast for Thursday July 30 2009 51438 4 Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec 51435 1 Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec 51435 2 Victory Pharma Inc Announces FDA Accepts MGX006 NDA for Review 51430 1 Victory Pharma Inc Announces FDA Accepts MGX006 NDA for Review 51430 2

[0] ESA and World Bank move toward closer collaboration [0] Bowman creates graphic translation of climate change data [0] CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions

... time when peeking at another student,s work during class ... when only televisions had clickers, not classrooms. , Starting ... biology lab sections at Worcester Polytechnic Institute (WPI) have ... that promises to improve student-achievement and enhance teaching during ...

... the waning months of the First World War, a ... subtype H1N1), swept the United States, Europe and Asia ... ensuing pandemic claimed up to 100 million victims, most ... rapidly progressing pneumonia. Many died within days of the ...

... the elevated carbon dioxide (CO 2 ) levels predicted for ... atmospheric conditions, researchers report, a finding that will help fine-tune ... CO 2 levels rise. , The study, from researchers ... Agriculture, appears this week in the Proceedings of the ...

Other Biology News:At WPI, some students are learning it's OK to peek 2 At WPI, some students are learning it's OK to peek 3 At WPI, some students are learning it's OK to peek 4 Shades of 1918? New study compares avian flu with a notorious killer from the past 2 Shades of 1918? New study compares avian flu with a notorious killer from the past 3 Shades of 1918? New study compares avian flu with a notorious killer from the past 4 Shades of 1918? New study compares avian flu with a notorious killer from the past 5 High CO2 boosts plant respiration, potentially affecting climate and crops 2

At WPI, some students are learning it's OK to peek Shades of 1918? New study compares avian flu with a notorious killer from the past High CO2 boosts plant respiration, potentially affecting climate and crops

...

Use as the souce of CETP enzyme for screening CETP inhibitors. Use in conjunction with the CETP activity assay kit (K601-100)....

For mRNA Differential Display with three one-base anchored oligo-dT primers and rationally designed arbitrary 13mers. These kits feature the latest generation of isotopic mRNA Differential Display t...

22 x 50 mm; No. 1 thickness range: 0.13 to 0.17 mm, suitable for work in histology, cytology, urinalysis and microbiology, precleaned, store at room temperature ...

Biology Products:

AcroPrep 96 Filter Plates, 1 mL from Pall Life Sciences Rabbit Serum from BioVision RNAimage Kit from GenHunter Cover Glasses from Santa Cruz Biotechnology, Inc.

Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunothe...(so developing a new class of drugs for t...)